ImmunityBio Inc

Investor insights: Simon Barry J’s recent insider sell‑offs on ImmunityBio stock are routine portfolio moves, not a red flag for the company’s growing oncology pipeline and strong financials.

Insider buying shows confidence in ImmunityBio’s growth—executives buy low, sell high and exercise options amid Anktiva sales and new approvals.

Insider trading at ImmunityBio shows Patrick Soon‑Shiong buying RSUs then selling shares, hinting at short‑term liquidity moves amid an upcoming ASCO data release.

Insider buying spree at ImmunityBio signals confidence ahead of ASCO symposium – CFO & CEO net gains hint at future upside, while RSU sales show cash‑management strategy.

Simon Barry J. sells 151,967 ImmunityBio shares via a Rule 10b5‑1 plan—insider liquidity, not loss of confidence, amid a 203% rally and strong oncology pipeline.